

## **XBiotech to Present at UBS Global Healthcare Conference**

May 1, 2013 1:03 PM ET

PR Newswire  
AUSTIN, Texas  
May 1, 2013

AUSTIN, Texas, May 1, 2013 /[PRNewswire](#)/ -- XBiotech announced today that John Simard, Chairman, President & Chief Executive Officer, will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20<sup>th</sup> at 1:30pm ET. The conference will take place at the Sheraton New York Hotel May 20-22, 2013.

John Simard remarked "XBiotech is delighted to be invited by UBS to present at this prestigious venue. UBS is one of the greatest financial institutions in the world and we are indeed honored to be asked to share our story at their conference."

### **About *True Human*<sup>TM</sup> Antibodies**

*True Human* antibodies represent the next generation of therapeutic antibodies. *True Human* antibodies are "invisible" to the body's immune system and thus have the potential for better safety, efficacy and patient tolerability compared to earlier generation antibody therapeutics.

### **About XBiotech**

XBiotech is pioneering breakthrough therapies that improve the safety and efficacy of antibody therapeutics. The Company's lead product candidate inhibits chronic sterile inflammation by targeting IL-1a, a master regulator of inflammation. The clinical development program addresses tremendous unmet medical need in multiple disease indications including, acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease. XBiotech is also revolutionizing scalable, flexible manufacturing systems for the production of biological therapies. Using minimal infrastructure and disposable bioreactor technology – to dramatically reduce capital requirements, operating complexity, and lead times - the Company has established a compelling commercialization path for its *True Human* antibody platform. XBiotech is building on a foundation of groundbreaking therapies, innovation and a commitment to unmet medical needs worldwide. For more information on how XBiotech is advancing human monoclonal antibody therapy please visit [www.xbiotech.com](http://www.xbiotech.com).

### **Contact:**

Investors:  
Erika Geimonen, Ph.D.  
XBiotech  
[info@xbiotech.com](mailto:info@xbiotech.com)  
512.386.2906

SOURCE XBiotech